CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
NAVS Naphthalan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02920658
NCT02920658Phase 2Completed

Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues

Ivan Alajbeg·interventional·Posted Sep 30, 2016·Updated Sep 30, 2016

In Brief

A Phase 2 clinical trial evaluating NAVS Naphthalan and 0.05% Betamethasone dipropionate for Oral Lichen Planus and Recurrent Aphthous Stomatitis. Completed, enrolled 57 participants across 1 site.

Detailed Summary

This study evaluates the effectiveness of topical NAVS naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Half of participants with OLP and RAS will receive topical NAVS naphthalan in adhesive paste, while the other half will receive 0.05%-betamethasone dipropionate in adhesive paste. Our hypothesis is that NAVS could be efficient in the treatment of OLP and RAS, with effects comparable to that of topical steroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCroatia

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2016
Enrollment StartDec 1, 2010
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.8 years ago

Interventions

NAVS Naphthalandrug

0.05% Betamethasone dipropionatedrug